Next Steps for Trastuzumab Emtansine After the KAMILLA Trial
Rachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.
Examining the KAMILLA Trial of Trastuzumab Emtansine in Metastatic Breast Cancer
Rachel Wuerstein, MD, discusses the KAMILLA trial of trastuzumab emtansine in metastatic breast cancer for both a global and Asian cohort.
Predictions for Future Use of T-DM1 in HER2+ Metastatic Breast Cancer
Rachel Wuerstein, MD, of the Unïversität Müchen, discusses the KAMILLA trial and the benefit of trastuzumab emtansine.